Celyad Oncology Announces the Termination of Its American Depository Receipt Program
September 25 2023 - 4:01PM
Business Wire
Regulatory News:
Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the
“Company”) today announces that Citibank, N.A., as depositary
(“Citibank”), shall issue the notice of terminating its American
Depository Receipt program (“ADR Program”) of American Depositary
Shares representing ordinary shares (“ADSs”) to the holders of ADSs
according to the requirements under the deposit agreement. The ADR
Program and the deposit agreement will be terminated on October 26,
2023 (the “Termination Date”).
Prior to termination of the deposit agreement, ADS holders are
entitled to surrender their ADSs to Citibank for cancellation, in
accordance with the terms of the deposit agreement, and receive the
underlying ordinary shares of the Company. Holders of ADSs should
contact Citibank or, to the extent holders are holding ADSs through
a bank, broker or other nominee, such holders should contact such
bank, broker or nominee with any questions regarding the ADSs.
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company
dedicated to pioneering the discovery and advancement of
revolutionary technologies for chimeric antigen receptor (CAR)
T-cells. Its primary objective is to unlock the potential of its
proprietary technology platforms and intellectual property,
enabling to be at the forefront of developing next-generation CAR
T-cell therapies. By fully leveraging its innovative technology
platforms, Celyad Oncology aims to maximize the transformative
impact of its candidate CAR T-cell therapies and redefine the
future of CAR T-cell treatments. Celyad Oncology is based in
Mont-Saint-Guibert, Belgium. For more information, please visit
www.celyad.com.
Forward-looking statements
This release may contain forward-looking statements, within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, statements regarding beliefs about and
expectations for the Company’s updated strategic business model,
including associated potential benefits, transactions and
partnerships, statements regarding the potential value of the
Company’s IP, and statements regarding the termination of the ADR
program and of the deposit agreement. The words “will,” “believe,”
“potential,” “continue,” “target,” “project,” “should” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this release
are based on management’s current expectations and beliefs and are
subject to a number of known and unknown risks, uncertainties and
important factors which might cause actual events, results,
financial condition, performance or achievements of Celyad Oncology
to differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks related to the material uncertainty about
the Company’s ability to continue as a going concern; the Company’s
ability to realize the expected benefits of its updated strategic
business model; the Company’s ability to develop its IP assets and
enter into partnerships with outside parties; the Company’s ability
to enforce its patents and other IP rights; the possibility that
the Company may infringe on the patents or IP rights of others and
be required to defend against patent or other IP rights suits; the
possibility that the Company may not successfully defend itself
against claims of patent infringement or other IP rights suits,
which could result in substantial claims for damages against the
Company; the possibility that the Company may become involved in
lawsuits to protect or enforce its patents, which could be
expensive, time-consuming, and unsuccessful; the Company’s ability
to protect its IP rights throughout the world; the potential for
patents held by the Company to be found invalid or unenforceable;
and other risks identified in Celyad Oncology’s U.S. Securities and
Exchange Commission (SEC) filings and reports, including in the
latest Annual Report on Form 20-F filed with the SEC and subsequent
filings and reports by Celyad Oncology. These forward-looking
statements speak only as of the date of publication of this
document and Celyad Oncology’s actual results may differ materially
from those expressed or implied by these forward-looking
statements. Celyad Oncology expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
Source: Celyad Oncology SA
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925711344/en/
Celyad Oncology Contacts:
Investor Contact: David Georges VP Finance and
Administration investors@celyad.com
Media Contact: Caroline Lonez R&D Communications and
Business Development communications@celyad.com
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2024 to May 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From May 2023 to May 2024